Optimizing inhaled corticosteroid therapy in children with chronic asthma

Area of Science:

• Pediatric Pulmonology
• Pharmacology
• Allergy and Immunology

Background:

• Asthma is the most prevalent chronic childhood illness.
• Inhaled corticosteroids (ICS) are the cornerstone for managing persistent asthma by reducing airway inflammation.
• Early diagnosis and treatment are crucial for asthma control, lung function normalization, and preventing irreversible airway damage.

Purpose of the Study:

• To review the efficacy and safety of inhaled corticosteroids (ICS) in pediatric asthma management.
• To highlight strategies for improving patient compliance with ICS therapy.
• To discuss factors influencing optimal ICS delivery and selection for children.

Main Methods:

• Review of current literature on ICS use in pediatric asthma.
• Analysis of factors affecting ICS efficacy and side effect profiles.
• Discussion of drug delivery systems and patient education strategies.

Main Results:

• ICS therapy is highly effective for persistent asthma, with minimal side effects when used at the lowest effective dose.
• Patient compliance is a significant challenge, but can be improved through simplified regimens, proper inhaler technique, and education.
• Budesonide inhalation suspension is suitable for children as young as 12 months, delivered via nebulizer for passive inhalation.

Conclusions:

• Optimizing ICS therapy in children requires selecting effective, low-side-effect medications like budesonide.
• User-friendly delivery systems and consistent patient/caregiver education are vital for successful asthma management.
• Titrating ICS to the minimum effective dose is essential to minimize potential systemic adverse effects.